JPS6250475B2 - - Google Patents
Info
- Publication number
- JPS6250475B2 JPS6250475B2 JP58139385A JP13938583A JPS6250475B2 JP S6250475 B2 JPS6250475 B2 JP S6250475B2 JP 58139385 A JP58139385 A JP 58139385A JP 13938583 A JP13938583 A JP 13938583A JP S6250475 B2 JPS6250475 B2 JP S6250475B2
- Authority
- JP
- Japan
- Prior art keywords
- substance
- spf
- physiologically active
- culture
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000013543 active substance Substances 0.000 claims description 38
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 15
- 238000000862 absorption spectrum Methods 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 238000000921 elemental analysis Methods 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical group CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 35
- 239000002609 medium Substances 0.000 description 22
- 230000001580 bacterial effect Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 241000193996 Streptococcus pyogenes Species 0.000 description 11
- 229940056360 penicillin g Drugs 0.000 description 11
- 238000003756 stirring Methods 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Description
【発明の詳細な説明】
本発明は、新規な生理活性物質SPF―1及びそ
の製法に関するものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel physiologically active substance SPF-1 and a method for producing the same.
更に詳細には、本発明は、抗腫瘍性物質として
きわめて有望な生理活性物質SPF―1及びその製
法に関するものである。 More specifically, the present invention relates to SPF-1, a physiologically active substance that is extremely promising as an antitumor substance, and a method for producing the same.
従来、溶連菌の生菌体を弱毒化して製剤化した
ものは、すでに制癌剤として使用されている。 Conventionally, attenuated viable bacterial cells of hemolytic streptococcus have been prepared into preparations and have already been used as anticancer drugs.
また、ストレプトコツカス・ピオゲネス菌体を
破砕後水または塩類溶液で有効成分を抽出し、有
機溶媒を加えて、抗腫瘍性成分を沈澱として、回
収する方法(特公昭38−1647)、溶連菌を溶菌酵
素、リゾチーム、セルラーゼまたは蛋白質分解酵
素により、溶菌し、活性画分を水溶性区分として
分画する方法(英国特許第1163865号)などが知
られている。 In addition, a method of crushing Streptococcus pyogenes bacterial cells, extracting the active ingredients with water or a salt solution, adding an organic solvent, and recovering the antitumor ingredients as precipitates (Japanese Patent Publication No. 38-1647), Known methods include lysing bacteria with a lytic enzyme, lysozyme, cellulase, or proteolytic enzyme and fractionating the active fraction as a water-soluble fraction (British Patent No. 1163865).
このように、ストレプトコツカス属細菌そのも
のもしくはその菌体成分に抗腫瘍活性があること
は広く知られているのであるが、従来知られたも
のは、菌体もしくは水可溶性もしくは不溶性高分
子細胞構成物質であるに過ぎなかつた。菌体もし
くは菌体内から有効成分を単離しようとすれば、
菌体を溶菌したり、機械的に破砕したりして全体
を分画しなければならなかつた。このような処理
によれば、精製は複雑となり、有効成分の単離は
きわめて困難であつた。実際に分離し、有効成分
として測定された例では分子量150000の蛋白質が
知られている。(特公昭48−43841)
本発明者らは、よりすぐれた抗腫瘍性有効成分
を溶連菌に求めて鋭意研究した結果、全く新規な
生理活性物質SPF―1を培養液中に見出すに至つ
たのである。 As described above, it is widely known that Streptococcus bacteria themselves or their bacterial cell components have antitumor activity, but what was previously known was that the Streptococcus bacteria themselves or their cell components have antitumor activity. It was nothing more than matter. If you try to isolate the active ingredient from the bacterial body or inside the bacterial body,
It was necessary to fractionate the entire bacterial body by lysing it or mechanically crushing it. Such treatment complicates purification and makes it extremely difficult to isolate the active ingredient. A protein with a molecular weight of 150,000 is known to have been actually isolated and measured as an active ingredient. (Japanese Patent Publication No. 48-43841) As a result of intensive research in search of superior anti-tumor active ingredients for hemolytic streptococci, the present inventors discovered a completely new physiologically active substance SPF-1 in the culture solution. be.
本発明の生理活性物質SPF―1は培養中菌体外
に排出され、培養液中に存在するようになるの
で、菌体を過して除去し、培養液を精製すれ
ばよいので、単離はかなり容易なものとなる。 The physiologically active substance SPF-1 of the present invention is excreted outside the bacterial cells during culture and becomes present in the culture solution, so it can be removed by passing through the bacterial cells and the culture solution can be purified. becomes quite easy.
本発明の生理活性物質SPF―1は培養液中に排
出されるとともに、分子量が約500〜7000といち
じるしく小さいことによつて特長づけられる。 The physiologically active substance SPF-1 of the present invention is excreted into the culture medium and is characterized by its extremely small molecular weight of approximately 500 to 7,000.
従来、溶連菌関連の生理活性物質で、培養液中
に蓄積されたものはなく、また分子量も数万以下
のものは知られておらず、本発明の生理活性物質
SPF―1は全く新規な物質と認められる。 Until now, there have been no physiologically active substances related to streptococcus that have accumulated in the culture solution, and no known molecular weight of less than tens of thousands of thousands of pounds.
SPF-1 is recognized as a completely new substance.
また、本発明の生理活性物質SPF―1は、元素
分析、呈色反応等からペプチド性物質と認められ
るが、紫外線吸収スペクトルで特異な吸収があ
り、従来広く知られた抗腫瘍活性物質などとも明
らかに相違する物質であつて、物質として新規な
ものと認められるものである。 In addition, although the physiologically active substance SPF-1 of the present invention is recognized as a peptide substance based on elemental analysis and color reaction, it has a unique absorption in the ultraviolet absorption spectrum and is not considered to be a widely known antitumor active substance. It is a substance that is clearly different and is recognized as a new substance.
本発明は、ストレプトコツカス属に属する生理
活性物質SPF―1生産菌を培養し、培養物から生
理活性物質SPF―1を採取することを特徴とする
生理活性物質SPF―1の製法を包含するものであ
る。 The present invention includes a method for producing the physiologically active substance SPF-1, which is characterized by culturing a physiologically active substance SPF-1-producing bacterium belonging to the genus Streptococcus and collecting the physiologically active substance SPF-1 from the culture. It is something.
本発明においては、ストレプトコツカス属に属
する生理活性物質SPF―1生産菌が広く使用され
るが、その一例としてストレプトコツカス・ピオ
ゲネス(Streptococcus pyogenes)ATCC21060
があげられる。 In the present invention, bacteria that produce the physiologically active substance SPF-1 belonging to the genus Streptococcus are widely used; one example is Streptococcus pyogenes ATCC21060.
can be given.
培養液は、肉エキス培地、酵母エキス培地、ブ
レイン・ハート・インフユージヨン培地(BHI培
地)等の天然培地がよく用いられるが、ストレプ
トコツカス属細菌が有効に生育する培地であれば
炭素源、窒素源等含んだ一般培地も使用すること
ができる。 Natural media such as meat extract medium, yeast extract medium, and brain heart infusion medium (BHI medium) are often used as the culture medium, but any medium that allows Streptococcus bacteria to grow effectively can be used as a carbon source. A general medium containing a nitrogen source, etc. can also be used.
培養はPH6.0〜8.0、好ましくは6.8〜7.2で30〜
40℃好ましくは35〜37℃であり嫌気的に静置培養
をおこなうのが一般的であるが、その他攪拌培養
等の変法も採用することができる。 Culture at PH6.0-8.0, preferably 6.8-7.2 and 30-30
It is common to perform static culture at 40°C, preferably 35 to 37°C, in an anaerobic manner, but other modified methods such as agitation culture may also be employed.
本発明においては、培養中の適当な時期にペニ
シリン又はその関連物質を添加することが、生理
活性物質SPF―1の取得に重要な役割をはたすこ
とになる。 In the present invention, adding penicillin or its related substances at an appropriate time during culture plays an important role in obtaining the physiologically active substance SPF-1.
ペニシリン又はその関連物質の添加時期は37℃
の培養で対数増殖期にかかつて後3〜15時間の
間、特に5〜10時間が好ましい。その後1時間乃
至20時間好ましくは5〜15時間そのまま培養を続
けることによつて、培養液中に生理活性物質SPF
―1を多量蓄積させることができる。 The timing of addition of penicillin or related substances is 37℃.
A period of 3 to 15 hours, particularly 5 to 10 hours after the culture reaches logarithmic growth phase is preferred. After that, by continuing the culture for 1 hour to 20 hours, preferably 5 to 15 hours, the physiologically active substance SPF is added to the culture solution.
-1 can be accumulated in large quantities.
ペニシリン又はその関連物質としてはすでに知
られたペニシリンと類似の作用をもつ関連物質で
あればいかなるものでもよいが、ペニシリンGが
普通用いられる。添加量はペニシリンGで100〜
3000単位/ml、好ましくは1000単位/ml培養液程
度で十分である。 Penicillin or its related substances may be any known related substances that have similar effects to penicillin, but penicillin G is commonly used. The amount added is 100~ for penicillin G.
About 3000 units/ml, preferably 1000 units/ml of culture solution is sufficient.
得られた培養液は、遠心分離によつて菌体を除
去し、液に硫安を添加し50〜80%飽和度の画分
を分取して得られた沈澱物を安定剤を加えた緩衝
液溶解する。 The resulting culture solution was centrifuged to remove bacterial cells, ammonium sulfate was added to the solution, and a fraction with a saturation level of 50 to 80% was collected. The resulting precipitate was added to a buffer containing a stabilizer. Dissolve in liquid.
生理活性物質SPF―1含有液は凍結状態で又は
凍結乾燥して保存することができる。この物質は
必要に応じてイオン交換体あるいはゲル過剤と
接触せしめてさらに精製することができる。イオ
ン交換体としてはイオン交換樹脂、イオン交換セ
ルローズ、イオン交換セフアデツクス(フアルマ
シア社製)等が用いられ、ゲル過剤としては、
トヨパールHW50FまたはHW―50SF(東洋曹達
(株)製)、セフアデツクス(フアルマシア社製)等
が用いられる。またカルシウムホスフエートゲル
はそのままでも使用できるが、ハイドロキシルア
パタイトの形で使用するのが便利である。前記の
ようにして得られた物質の水溶液をこれらのイオ
ン交換体又はゲル過剤を充填したカラムに、適
当な速度で通過せしめるか、あるいはイオン交換
体又はゲル過剤を入れた一定容器中に一度にそ
の水溶液を加えて、これらの処理剤と有効物質を
接触させる。溶出は適当な塩濃度とPHの緩衝液を
用いて行なう。イオン交換体、ゲル過剤又はカ
ルシウムホスフエートゲルは2種以上組合わせて
用いることもできる。たとえばDEAEセフアデツ
クスと接触させ、溶出した液を更にトヨパール
HW50Fまたは50SFと接触させそして溶出を行な
うと、更に精製の効果を上げることができる。 A solution containing the physiologically active substance SPF-1 can be stored in a frozen state or by lyophilization. This substance can be further purified by contacting it with an ion exchanger or gelling agent, if necessary. As the ion exchanger, ion exchange resin, ion exchange cellulose, ion exchange Cephadex (manufactured by Pharmacia), etc. are used, and as the gelling agent,
Toyo Pearl HW50F or HW-50SF (Toyo Soda
Co., Ltd.), Cephadex (Pharmacia Co., Ltd.), etc. are used. Although calcium phosphate gel can be used as it is, it is convenient to use it in the form of hydroxylapatite. The aqueous solution of the substance obtained as described above is passed through a column filled with these ion exchangers or gelling agents at an appropriate speed, or it is poured into a container containing the ion exchanger or gelling agent. The aqueous solution is added all at once to bring these treatment agents and active substances into contact. Elution is performed using a buffer solution with appropriate salt concentration and pH. Two or more ion exchangers, gelling agents, or calcium phosphate gels may be used in combination. For example, contact with DEAE Cephadex and add the eluted solution to Toyopearl.
Contact with HW50F or 50SF and elution can further improve the purification effect.
ここに得られた物質はペプチド性物質で、凍結
乾燥すると白色の粉末となる。 The substance obtained here is a peptide substance, which becomes a white powder when freeze-dried.
次に、生理活性物質SPF―1の理化学的性質を
示す。 Next, we will show the physicochemical properties of the physiologically active substance SPF-1.
1 元素分析
C:41.26%、H:4.91%、N:6.52%
〓 〓 〓
36.64% 4.10% 5.40%
2 分子量
ゲル過法による測定では、分子量約500〜
7000である。1 Elemental analysis C: 41.26%, H: 4.91%, N: 6.52% 〓 〓 〓 36.64% 4.10% 5.40% 2 Molecular weight When measured by gel permeation method, the molecular weight is approximately 500 ~
It is 7000.
3 分解点
本物質は170℃で褐変し、200℃になると黒色
となり分解する。3. Decomposition point This substance turns brown at 170℃ and turns black at 200℃ and decomposes.
4 比旋光度
〔α〕20 D=+63.3〜64.3゜(c=1.04)
5 紫外線吸収スペクトル
本物質の3.3%の水溶液の紫外線吸収スペク
トルは第1図に示され、3.1%の水溶液の紫外
線吸収スペクトルは第2図に示される。いずれ
も、257nm、265nm、280nm、287nmに吸収が
みられ、特徴的である。4 Specific rotation [α] 20 D = +63.3 to 64.3° (c = 1.04) 5 Ultraviolet absorption spectrum The ultraviolet absorption spectrum of a 3.3% aqueous solution of this substance is shown in Figure 1, and the ultraviolet absorption spectrum of a 3.1% aqueous solution The absorption spectrum is shown in FIG. All have characteristic absorption at 257nm, 265nm, 280nm, and 287nm.
6 赤外線吸収スペクトル 第3図に示される。6 Infrared absorption spectrum It is shown in FIG.
7 溶剤に対する溶解性
水に可溶であるが、メタノール、エタノー
ル、n―ブタノール、イソブタノール、n―プ
ロパノール、n―ヘキサン、クロロホルム、ア
セトン、メチルイソブチルケトン、エチルエー
テル等の溶剤には不溶である。7 Solubility in solvents Soluble in water, but insoluble in solvents such as methanol, ethanol, n-butanol, isobutanol, n-propanol, n-hexane, chloroform, acetone, methyl isobutyl ketone, and ethyl ether. .
8 塩基性、酸性、中性の区別 本物質の0.85%水溶液のPHは6.5である。8 Distinction between basic, acidic, and neutral The pH of a 0.85% aqueous solution of this substance is 6.5.
9 物質の色 白色粉末状である。9 Color of matter It is a white powder.
10 呈色反応
ニンヒドリン反応 +
ビユウレツト反応 +
モーリツシユ反応 −
デイシエ反応 −
アンスロン反応 −
システイン硫酸反応 −
11 安定化
本物質はL―システイン、ジチオスレイトー
ル(DTT)、グリセロール、アルブミン、グロ
ブリン、(NH4)2SO4、食塩等の添加によつて安
定化される。10 Color reaction Ninhydrin reaction + Biuretz reaction + Mauritsch reaction - Decier reaction - Anthrone reaction - Cysteine sulfate reaction - 11 Stabilization This substance is L-cysteine, dithiothreitol (DTT), glycerol, albumin, globulin, (NH 4 ) 2 Stabilized by adding SO 4 , salt, etc.
次に本発明の実施例を示す。 Next, examples of the present invention will be shown.
なお実施例における生理活性物質SPF―1の活
性単位の測定は鵜高法(Journal of Antibiotics
vol35No.10 1319〜1325OCT1982)によつた。測
定には高分子透過性大腸菌変異株MP―2
(FERM―P5432)(Agric.Biol.Chem.43 371
(1979)を使用してMP―2に対する抗菌活性を指
標としてバイオ・アツセイする。 In the Examples, the activity unit of the physiologically active substance SPF-1 was measured using the Udaka method (Journal of Antibiotics
vol35No.10 1319-1325OCT1982). For measurement, polymer-permeable E. coli mutant strain MP-2 was used.
(FERM-P5432) (Agric.Biol.Chem.43 371
(1979) to conduct a bioassay using antibacterial activity against MP-2 as an indicator.
すなわち、バクト・アンチバイオチツクメデイ
アム3(デイフコ社製品)1.75%、寒天1.3%よ
り成る培地(M3培地)を120℃、15分加熱殺菌
し、20mlずつシヤーレに分注し、放冷してプレー
ト培地を調製する。 That is, a medium ( M3 medium) consisting of 1.75% Bacto Antibiotic Medium 3 (product of Difco) and 1.3% agar was heat sterilized at 120°C for 15 minutes, dispensed into 20ml portions into a shear dish, and allowed to cool. Prepare plate medium.
一方、ペプトン0.5%、肉エキス0.5%、
NaCl0.3%、寒天0.8%より成る培地を120℃、15
分加熱殺菌する。その後42℃の恒温槽に保ち、培
地の温度が42℃になつたらあらかじめ37℃で17時
間培養したMP―2菌を1ml中に104個の細胞が存
在する様に培地中に加える。ピペツトによつて2
mlを採取し、あらかじめ作製して置いたM3培地
表面上に加え、すばやく均一にひろげ固化させ
る。生理活性物質SPF―1を含む被験液を適当に
希釈して、その溶液0.05mlをペーパー・デイスク
(直径8mm)(東洋紙)にしみ込ませる。このペ
ーパー・デイスクを前記作製プレート上に置き、
37℃で17時間培養し、生理活性物質SPF―1によ
つてできる阻止円の大きさを測定する。阻止円の
直径10mmを与えるSPF―1の濃度を1単位(1u)
と定義する。 Meanwhile, peptone 0.5%, meat extract 0.5%,
A medium consisting of 0.3% NaCl and 0.8% agar was heated at 120℃ for 15 minutes.
Sterilize by heating for a minute. Thereafter, the medium is kept in a constant temperature bath at 42°C, and when the temperature of the medium reaches 42°C, MP-2 bacteria, which have been previously cultured at 37°C for 17 hours, are added to the medium so that 10 4 cells are present in 1 ml. by pipette 2
Collect ml and add it to the surface of M3 medium prepared in advance and spread quickly and uniformly to solidify. Appropriately dilute the test solution containing the physiologically active substance SPF-1, and soak 0.05 ml of the solution into a paper disk (diameter 8 mm) (Toyo Shi). Place this paper disk on the production plate,
Culture at 37°C for 17 hours, and measure the size of the inhibition zone created by the physiologically active substance SPF-1. 1 unit (1u) concentration of SPF-1 that gives a diameter of inhibition circle of 10mm
It is defined as
実施例 1
次の組成の培地A2に、
肉エキス 1%
ポリプトンン 1%
Nacl 0.5%PH=7.1
Streptococcus pyogenes ATCC21060を(BHI
培地100mlに接種して37℃、8時間静置培養によ
り前培養をおこなつた培養液100mlを接種し、37
℃、15hr攪拌しながら嫌気的に培養後、ペニシリ
ンG1000単位/mlを添加し、更に培養を5hr継続
する。得られた培養液を遠心分離し、菌体を除去
した。Example 1 Streptococcus pyogenes ATCC21060 (BHI
Inoculate 100 ml of culture medium and pre-culture by static culture at 37℃ for 8 hours.
After culturing anaerobically at 15°C with stirring for 15 hours, 1000 units/ml of penicillin G was added and the culture was continued for an additional 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液は生理活性物質SPF―1が120単位/
ml含有されていた。 The culture solution contains 120 units of the physiologically active substance SPF-1.
It contained ml.
実施例 2
次の組成の培地B2に、
酵母エキス 3.0%
BHI 1.0%
ポリペプトン 1.0%
マルトース 0.3%
KH2PO4 0.1%
MgSO4・7H2O 0.02%
PH=7.2
Streptococcus pyogenes ATCC21060を実施
例1と同様に前培養した培養液100mlを接種し、
37℃、15hr攪拌しながら嫌気的に培養後、ペニシ
リンG1000単位/mlを添加し、更に培養を5hr継
続する。得られた培養液を遠心分離し、菌体を除
去した。Example 2 Yeast extract 3.0% BHI 1.0% Polypeptone 1.0% Maltose 0.3% KH 2 PO 4 0.1% MgSO 4 7H 2 O 0.02% PH = 7.2 Streptococcus pyogenes ATCC21060 was added to medium B2 with the following composition as in Example 1. Inoculate 100ml of precultured culture solution into
After culturing anaerobically at 37°C for 15 hours with stirring, 1000 units/ml of penicillin G was added, and the culture was continued for an additional 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が152単
位/ml含有されていた。 The culture solution contained 152 units/ml of the physiologically active substance SPF-1.
実施例 3
次の組成の培地C2に、
肉エキス 1%
ポリペプトン 1%
NaCl 0.5%
マルトース 0.3%
KH2PO4 0.1%
MgSO4・7H2O 0.02%
PH=7.1
Streptococcus pyogenes ATCC21060を実施
例1と同様に前培養した培養液100mlを接種し、
37℃、15hr攪拌しながら嫌気的に培養後、ペニシ
リンG1000単位/mlを添加し、更に培養を5hr継
続する。得られた培養液を遠心分離し、菌体を除
去した。Example 3 Meat extract 1% Polypeptone 1% NaCl 0.5% Maltose 0.3% KH 2 PO 4 0.1% MgSO 4 7H 2 O 0.02% PH=7.1 Streptococcus pyogenes ATCC21060 was added to medium C2 with the following composition as in Example 1. Inoculate 100ml of precultured culture solution into
After culturing anaerobically at 37°C for 15 hours with stirring, 1000 units/ml of penicillin G was added, and the culture was continued for an additional 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が240単
位/ml含有されていた。 The culture solution contained 240 units/ml of the physiologically active substance SPF-1.
実施例 4
次の組成の培地D2に、
肉エキス 1.5%
ポリペプトン 1.0%
NaCl 0.5%
カザミノ酸 0.5%
酵母エキス 0.2%
PH=7.1
Streptococcus pyogenes ATCC21060を実施
例1と同様に前培養した培養液100mlの−20℃保
存物を接種し、37℃、15hr攪拌しながら嫌気的に
培養後、ペニシリンG1000単位/mlを添加し、更
に培養を5hr継続する。得られた培養液を遠心分
離し、菌体を除去した。Example 4 Meat extract 1.5% Polypeptone 1.0% NaCl 0.5% Casamino acids 0.5% Yeast extract 0.2% PH=7.1 Streptococcus pyogenes ATCC21060 was precultured in the same manner as in Example 1, and 100 ml of the culture medium D2 with the following composition was added to the medium D2. After inoculating the cells stored at 20°C and culturing them anaerobically at 37°C for 15 hours with stirring, 1000 units/ml of penicillin G was added, and the culture was continued for an additional 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が108単
位/ml含有されていた。 The culture solution contained 108 units/ml of the physiologically active substance SPF-1.
実施例 5
次の組成の培地E2に、
肉エキス 1.5%
ポリペプトン 1.0%
NaCl 0.5%
カザミノ酸 0.25%
酵母エキス 0.25%
PH=7.1
Streptococcus pyogenes ATCC21060を実施
例1と同様に前培養した種培養液100mlを添加接
種し、37℃、15hr攪拌しながら嫌気的に培養後、
ペニシリンG1000単位/mlを添加し、更に培養を
5hr継続する。得られた培養液を遠心分離し、菌
体を除去した。Example 5 Meat extract 1.5% Polypeptone 1.0% NaCl 0.5% Casamino acids 0.25% Yeast extract 0.25% PH = 7.1 100 ml of the seed culture solution obtained by pre-cultivating Streptococcus pyogenes ATCC21060 in the same manner as in Example 1 was added to medium E2 with the following composition. After inoculation and culturing anaerobically at 37℃ for 15 hours with stirring,
Add 1000 units/ml of penicillin G and further culture.
Continues for 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が180単
位/ml含有されていた。 The culture solution contained 180 units/ml of the physiologically active substance SPF-1.
実施例 6
前記培地E2にStreptococcus pyogenes
ATCC21060を実施例1と同様に前培養した培養
液100mlの−20℃保存物を接種し、37℃、15hr攪
拌しながら嫌気的に培養後、ペニシリンG1000単
位/mlを添加し、更に培養を5hr継続する。得ら
れた培養後を遠心分離し、菌体を除去した。Example 6 Streptococcus pyogenes in the medium E2
Inoculate 100 ml of the culture solution stored at -20°C with ATCC21060 precultured in the same manner as in Example 1, and culture it anaerobically at 37°C for 15 hours with stirring. Then, add 1000 units/ml of penicillin G and continue culturing for 5 hours. continue. The resulting culture was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が100単
位/ml含有されていた。 The culture solution contained 100 units/ml of the physiologically active substance SPF-1.
実施例 7
下記の培地F2に、
肉エキス 3.0%
ポリペプトン 1.0%
NaCl 0.5%
カザミノ酸 0.5%
PH=7.1
Streptococcus pyogenes ATCC21060を実施
例1と同様にして前培養した培養100mlの−20℃
保存物を接種し、37℃、5.5hr攪拌しながら嫌気
的に培養後、ペニシリンG1000単位/mlを添加
し、更に培養を15hr継続する。得られた培養液を
遠心分離し、菌体を除去した。Example 7 Meat extract 3.0% Polypeptone 1.0% NaCl 0.5% Casamino acids 0.5% PH = 7.1 Streptococcus pyogenes ATCC21060 was precultured in the same manner as in Example 1 in the following medium F2.
After inoculating the stock and culturing anaerobically at 37°C for 5.5 hours with stirring, 1000 units/ml of penicillin G was added and the culture was continued for an additional 15 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が120単
位/ml含有された。 The culture solution contained 120 units/ml of the physiologically active substance SPF-1.
実施例 8
下記の培地G2に、
BHI 3.7%
ポリペプトン 0.5%
マルトース 0.3
KH2PO4 0.1%
MgSO4・7H2O 0.02%
PH=7.1
Streptococcus pyogenes ATCC21060を実施
例1と同様にして前培養した培養100mlを接種
し、37℃、15hr攪拌しながら嫌気的に培養後、ペ
ニシリンG1000単位/mlを添加し、更に培養を
5hr継続する。得られた培養液を遠心分離し、菌
体を除去した。Example 8 In the following medium G2, BHI 3.7% Polypeptone 0.5% Maltose 0.3 KH 2 PO 4 0.1% MgSO 4 7H 2 O 0.02% PH = 7.1 Streptococcus pyogenes ATCC 21060 was precultured in the same manner as in Example 1, and 100 ml of the culture was prepared. After inoculating and culturing anaerobically at 37°C for 15 hours with stirring, add 1000 units/ml of penicillin G and continue culturing.
Continues for 5 hours. The obtained culture solution was centrifuged to remove bacterial cells.
培養液には生理活性物質SPF―1が300単
位/ml含有されていた。 The culture solution contained 300 units/ml of the physiologically active substance SPF-1.
実施例 9
前記培地E3に、Streptococcus pyogenes
ATCC21060を37℃で8hr静置培養して得た種培養
液300mlを添加接種し、37℃、15hr攪拌しながら
嫌気的に培養後、ペニシリンG1000単位/mlを添
加し、更に培養を5hr継続する。得られた培養液
を遠心分離し、菌体を除去した。Example 9 In the medium E3, Streptococcus pyogenes
Add and inoculate 300 ml of the seed culture obtained by statically culturing ATCC21060 at 37°C for 8 hours. After culturing anaerobically at 37°C for 15 hours with stirring, add 1000 units/ml of penicillin G and continue culturing for an additional 5 hours. . The obtained culture solution was centrifuged to remove bacterial cells.
培養液3には生理活性物質SPF―1を56×
104単位含有していた。 Culture solution 3 contains 56x the physiologically active substance SPF-1.
It contained 10 4 units.
培養液は硫安を添加し50〜80%飽和度の画分
を分取して沈澱物を得た。この沈澱物は生理活性
物質SPF―1を50×104単位含有していた。 Ammonium sulfate was added to the culture solution, and a fraction with a saturation level of 50 to 80% was collected to obtain a precipitate. This precipitate contained 50×10 4 units of the physiologically active substance SPF-1.
この沈澱物全量を安定剤含有緩衝液300mlに溶
解し、溶解液をDEAE―セルロースカラム(5×
70cm)に加え、生理活性物質SPFを吸着させた。
これに0.3M NaCl溶液を用いて段階的に溶出さ
せ、活性部分を分取する。得られた活性は30×
104単位であつた。 The entire amount of this precipitate was dissolved in 300 ml of stabilizer-containing buffer solution, and the solution was transferred to a DEAE-cellulose column (5×
70cm), and the physiologically active substance SPF was adsorbed.
This is eluted stepwise using 0.3M NaCl solution, and the active portion is separated. The activity obtained is 30×
It was 10 4 units.
活性部分を緩衝液に対して透析し、次にDEAE
―セフアデツクスA―25のカラム(2.6×50cm)
加え、活性部分を吸着させ、それに燐酸緩衝液中
の食塩濃度を直線的に上昇させつつ溶出を行い、
活性部分を分取する。得られた活性は10.6×104
単位であつた。 The active moiety is dialyzed against buffer and then DEAE
-Sephadex A-25 column (2.6 x 50cm)
In addition, the active moiety is adsorbed, and elution is performed while linearly increasing the salt concentration in the phosphate buffer.
Separate the active portion. The activity obtained is 10.6×10 4
It was a unit.
更に、この溶出液を濃縮しゲル過材トヨパー
ルHW―50Fのカラム(2×100cm)に加え、活性
画分を分取する。得られた活性は2.2×104単位で
あつた。 Furthermore, this eluate is concentrated and applied to a gel filtration material Toyopearl HW-50F column (2 x 100 cm) to separate the active fraction. The activity obtained was 2.2×10 4 units.
ここに得られた溶出液を凍結乾燥し生理活性物
質SPF―1の白色粉末350mgを得た。 The eluate thus obtained was freeze-dried to obtain 350 mg of a white powder of the physiologically active substance SPF-1.
第1図は生理活性物質SPF―1 3.3%水溶液
の紫外線吸収スペクトルを示し、第2図は同じく
3.1%水溶液の紫外線吸収スペクトルを示し、第
3図は同同じく赤外線吸収スペクトルを示す。
Figure 1 shows the ultraviolet absorption spectrum of a 3.3% aqueous solution of the physiologically active substance SPF-1, and Figure 2 shows the same.
The ultraviolet absorption spectrum of a 3.1% aqueous solution is shown, and FIG. 3 also shows the infrared absorption spectrum.
Claims (1)
SPF―1。 1 元素分析 C:41.26%、H:4.91%、N:6.52% 〓 〓 〓 36.64% 4.10% 5.40% 2 分子量 ゲル過法による測定では、分子量約500〜
7000である。 3 分解点 本物質は170℃で褐変し、200℃になると黒色
となり分解する。 4 比旋光度 〔α〕20 D=+63.3〜64.3゜(c=1.04) 5 紫外線吸収スペクトル 本物質の3.3%の水溶液の紫外線吸収スペク
トルは第1図に示され、3.1%の水溶液の紫外
線吸収スペクトルは第2図に示される。いずれ
も、257nm、265nm、280nm、287nmに吸収が
みられ、特徴的である。 6 赤外線吸収スペクトル 第3図に示される。 7 溶剤に対する溶解性 水に可溶であるが、メタノール、エタノー
ル、n―ブタノール、イソブタノール、n―プ
ロパノール、n―ヘキサン、クロロホルム、ア
セトン、メチルイソブチルケトン、エチルエー
テル等の溶剤には不溶である。 8 塩基性、酸性、中性の区別 本物質の0.85%水溶液のPHは6.5である。 9 物質の色 白色粉末状である。 10 呈色反応 ニンヒドリン反応 + ビユウレツト反応 + モーリツシユ反応 − デイシエ反応 − アンスロン反応 − システイン硫酸反応 − 11 安定化 本物質はL―システイン、ジチオスレイトー
ル(DTT)、グリセロール、アルブミン、グロ
ブリン、(NH4)2SO4、食塩等の添加によつて安
定化される。 2 ストレプトコツカス属に属する生理活性物質
SPF―1生産菌を培養し、培養物から生理活性物
質SPF―1を採取することを特徴とする生理活性
物質SPF―1の製法。 3 ストレプトコツカス属に属する生理活性物質
SPF―1生産菌を培養するに際し、培養中の適当
な時期にペニシリン又はその関連物質を添加して
培養することを特徴とする特許請求の範囲第2項
に記載の生理活性物質SPF―1の製法。[Claims] 1. A physiologically active substance having the following physicochemical properties:
SPF-1. 1 Elemental analysis C: 41.26%, H: 4.91%, N: 6.52% 〓 〓 〓 36.64% 4.10% 5.40% 2 Molecular weight When measured by gel permeation method, the molecular weight is about 500~
7000. 3. Decomposition point This substance turns brown at 170℃ and turns black at 200℃ and decomposes. 4 Specific rotation [α] 20 D = +63.3 to 64.3° (c = 1.04) 5 Ultraviolet absorption spectrum The ultraviolet absorption spectrum of a 3.3% aqueous solution of this substance is shown in Figure 1, and the ultraviolet absorption spectrum of a 3.1% aqueous solution The absorption spectrum is shown in FIG. All have characteristic absorption at 257nm, 265nm, 280nm, and 287nm. 6 Infrared absorption spectrum Shown in Figure 3. 7 Solubility in solvents Soluble in water, but insoluble in solvents such as methanol, ethanol, n-butanol, isobutanol, n-propanol, n-hexane, chloroform, acetone, methyl isobutyl ketone, and ethyl ether. . 8. Distinction between basic, acidic, and neutral The pH of a 0.85% aqueous solution of this substance is 6.5. 9. Color of substance: White powder. 10 Color reaction Ninhydrin reaction + Biuretz reaction + Mauritsch reaction - Decier reaction - Anthrone reaction - Cysteine sulfate reaction - 11 Stabilization This substance is L-cysteine, dithiothreitol (DTT), glycerol, albumin, globulin, (NH 4 ) 2 Stabilized by adding SO 4 , salt, etc. 2 Physiologically active substances belonging to the genus Streptococcus
A method for producing the physiologically active substance SPF-1, which is characterized by culturing SPF-1 producing bacteria and collecting the physiologically active substance SPF-1 from the culture. 3 Physiologically active substances belonging to the genus Streptococcus
When culturing the SPF-1 producing bacteria, penicillin or a related substance is added to the culture at an appropriate time during the culture. Manufacturing method.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58139385A JPS6030689A (en) | 1983-08-01 | 1983-08-01 | Physiologically active substance spf-1 and its preparation |
CA000459394A CA1237085A (en) | 1983-08-01 | 1984-07-20 | Spf-100 and process for the preparation thereof |
GB08418745A GB2146028B (en) | 1983-08-01 | 1984-07-23 | Spf-100 and process for the preparation thereof |
AU31000/84A AU572529B2 (en) | 1983-08-01 | 1984-07-24 | Spf-100 and process for the preparation thereof |
CH3684/84A CH663033A5 (en) | 1983-08-01 | 1984-07-30 | SUBSTANCE-MIXTURE SAID "SPF-100" AND PROCESS FOR ITS PREPARATION. |
DE19843428017 DE3428017A1 (en) | 1983-08-01 | 1984-07-30 | SPF-100 AND METHOD FOR THE PRODUCTION THEREOF |
KR1019840004559A KR850002276A (en) | 1983-08-01 | 1984-07-31 | Manufacturing method of SPF-100 |
NL8402388A NL8402388A (en) | 1983-08-01 | 1984-07-31 | MEDICINAL PRODUCT SPF-100 AND METHOD FOR PREPARING THE SAME |
FR8412119A FR2550223B1 (en) | 1983-08-01 | 1984-07-31 | SPF-100 AND PREPARATION PROCESS |
SE8403914A SE461532B (en) | 1983-08-01 | 1984-07-31 | ANTI-CANCER AND IMMUNACTIVE SUBSTANCES (SPF-100) |
US06/746,514 US4656037A (en) | 1983-08-01 | 1985-06-19 | SPF-100 and process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP58139385A JPS6030689A (en) | 1983-08-01 | 1983-08-01 | Physiologically active substance spf-1 and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS6030689A JPS6030689A (en) | 1985-02-16 |
JPS6250475B2 true JPS6250475B2 (en) | 1987-10-24 |
Family
ID=15244077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58139385A Granted JPS6030689A (en) | 1983-08-01 | 1983-08-01 | Physiologically active substance spf-1 and its preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6030689A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU633809B2 (en) * | 1987-12-21 | 1993-02-11 | David G. Evans And Associates Pty. Ltd. | Sealed container |
-
1983
- 1983-08-01 JP JP58139385A patent/JPS6030689A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS6030689A (en) | 1985-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0956394A (en) | Preparation of hyaluronic acid by fermentation using streptococcus | |
JPH02117696A (en) | Antibiotics | |
JPS6344883A (en) | Novel hyaluronidase sd-678 and production thereof | |
CA1105404A (en) | .alpha.-AMYLASE INHIBITOR FROM A STREPTOMYCETE AND PROCESS FOR ITS PREPARATION | |
JPS6250475B2 (en) | ||
US4656037A (en) | SPF-100 and process for the preparation thereof | |
JPH0155275B2 (en) | ||
JP2654825B2 (en) | Novel cyclic inulooligosaccharide and method for producing the same | |
JPH0156077B2 (en) | ||
JPH0155274B2 (en) | ||
JPH0156078B2 (en) | ||
JPH026511B2 (en) | ||
Smith et al. | The Chemical Basis of the Virulence of Bacillus anthracis. VIII: Fractionation of the Intracellular Material of Bacillus anthracis | |
US3792160A (en) | Method of treating inflammation and composition therefor | |
JPH0155276B2 (en) | ||
US5482844A (en) | Enzyme intended for the fragmentation of N-acetylheparosan, production of preparations containing this enzyme and fragmentation processes using this enzyme | |
JPS6092218A (en) | Production of antitumor substance | |
JPS6326994B2 (en) | ||
JPS61219394A (en) | Production of hyaluronic acid through fermentation | |
JPS6216640B2 (en) | ||
FI59815B (en) | FREQUENCY REFRIGERATION FOR ALPHA-AMYLES INHIBITORS WITH STRUCTURAL STRUCTURES | |
JPS60104017A (en) | Antitumor agent | |
JPH0260318B2 (en) | ||
JPH0763365B2 (en) | Yeast cell wall lysing enzyme and method for extracting yeast cell component using the same | |
JPH0387178A (en) | Novel endodextrase, its production and production of isomaltooligosaccharide using the same enzyme |